Page last updated: 2024-10-29

staurosporine aglycone and Carcinoma, Anaplastic

staurosporine aglycone has been researched along with Carcinoma, Anaplastic in 2 studies

staurosporine aglycone: metabolite from culture broth of Nocardiopsis sp.; a neurotrophin antag; inhibits BDNF TrkB receptor

Research

Studies (2)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's1 (50.00)18.2507
2000's0 (0.00)29.6817
2010's1 (50.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Ng, YK1
Wong, EY1
Lau, CP1
Chan, JP1
Wong, SC1
Chan, AS1
Kwan, MP1
Tsao, SW1
Tsang, CM1
Lai, PB1
Chan, AT1
Lui, VW1
Zolfaghari, A1
Djakiew, D1

Other Studies

2 other studies available for staurosporine aglycone and Carcinoma, Anaplastic

ArticleYear
K252a induces anoikis-sensitization with suppression of cellular migration in Epstein-Barr virus (EBV)--associated nasopharyngeal carcinoma cells.
    Investigational new drugs, 2012, Volume: 30, Issue:1

    Topics: Anoikis; Antineoplastic Agents; Brain-Derived Neurotrophic Factor; Carbazoles; Carcinoma; Cell Adhes

2012
Inhibition of chemomigration of a human prostatic carcinoma cell (TSU-pr1) line by inhibition of epidermal growth factor receptor function.
    The Prostate, 1996, Volume: 28, Issue:4

    Topics: Alkaloids; Antibodies, Monoclonal; Carbazoles; Carcinogens; Carcinoma; Cell Movement; Dimethyl Sulfo

1996